Van Hout B A, Rutten F F, Lorijn R H
Erasmus Universiteit, Institute for Medical Technology Assessment, Rotterdam.
Ned Tijdschr Geneeskd. 1993 Feb 13;137(7):360-4.
The efficiency of prescribing HA-1A for sepsis patients is analysed by comparing direct medical costs and effects. Effects are estimated on the basis of published data from a randomised clinical trial. Costs are analysed by combining data from the same trial with expectations about hospital days. Average costs per life year gained are estimated at DF1. 25,000. Sensitivity analysis is applied and the efficiency of treating patients with HA1A is shown to depend highly on the expected duration of survival after successful treatment. This leads to the advice to take epidemiologic knowledge into special account before setting the indication for using HA-1A.
通过比较直接医疗成本和效果，分析了给脓毒症患者使用HA - 1A的效率。效果是根据一项随机临床试验的已发表数据估算的。通过将同一试验的数据与对住院天数的预期相结合来分析成本。每获得一个生命年的平均成本估计为25,000德国马克。应用了敏感性分析，结果表明用HA1A治疗患者的效率在很大程度上取决于成功治疗后的预期存活时间。这就建议在确定使用HA - 1A的适应症之前，要特别考虑流行病学知识。
